Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Mitochondrial dysregulation induced by an ulcerative colitis-associated pathobiont

EF 2021-22

Résumé
Inflammatory bowel disease (IBD) affects over 270,000 Canadians, with this number increasing each year. By 2030, it is expected that 400,000 Canadians will be living with IBD. The two major IBD subtypes are Crohn's disease (CD) and ulcerative colitis (UC). The intestinal inflammation seen in IBD is linked to exaggerated immune responses against an imbalanced gut microbiome and changes to critical intestinal epithelial cell (IEC) functions such as absorbing nutrients and forming a barrier against pathogens. IECs have high energy expenditure, thus requiring mitochondrial ATP production. Notably, IEC mitochondrial dysfunction is frequently observed in IBD patients. I hypothesize the aberrant mitochondrial function reflects the actions of microbes on the epithelium. In CD, mitochondrial dysregulation has been linked to the actions of a pathobiont. A pathobiont is an opportunistic microbe that is normally non-pathogenic in a healthy gut, but in susceptible individuals such as those predisposed to IBD, pathobionts outcompete healthy gut bacteria to colonize the intestine and cause disease. Whether pathobionts alter mitochondrial function in UC has yet to be examined. I propose to elucidate the structural and functional mitochondrial changes caused by p19A, a hemolysin toxin-producingE. colipathobiont isolated from UC patients. To study the effects of p19A on mitochondria, I will use both our in vivo novel mouse model of colitis and an ex vivo intestinal organoid model where mice or human patient IECs are cultured into a mini-gut structure. I will also explore the efficacy of mitochondria-targeted drugs to counteract the effects of p19A in both models. The proposed study will lead to better understandings of IBD pathogenesis and may help the development of novel IBD drugs.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466557
Name
Chan Jocelyn J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mitochondrial dysregulation induced by an ulcerative colitis-associated pathobiont
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Colitis; Epithelium; Gastrointestinal; Hemolysin; Inflammation; Inflammatory Bowel Disease; Microbiome; Mitochondria; Organoid; Pathobiont
Abstract
Inflammatory bowel disease (IBD) affects over 270,000 Canadians, with this number increasing each year. By 2030, it is expected that 400,000 Canadians will be living with IBD. The two major IBD subtypes are Crohn's disease (CD) and ulcerative colitis (UC). The intestinal inflammation seen in IBD is linked to exaggerated immune responses against an imbalanced gut microbiome and changes to critical intestinal epithelial cell (IEC) functions such as absorbing nutrients and forming a barrier against pathogens. IECs have high energy expenditure, thus requiring mitochondrial ATP production. Notably, IEC mitochondrial dysfunction is frequently observed in IBD patients. I hypothesize the aberrant mitochondrial function reflects the actions of microbes on the epithelium. In CD, mitochondrial dysregulation has been linked to the actions of a pathobiont. A pathobiont is an opportunistic microbe that is normally non-pathogenic in a healthy gut, but in susceptible individuals such as those predisposed to IBD, pathobionts outcompete healthy gut bacteria to colonize the intestine and cause disease. Whether pathobionts alter mitochondrial function in UC has yet to be examined. I propose to elucidate the structural and functional mitochondrial changes caused by p19A, a hemolysin toxin-producingE. colipathobiont isolated from UC patients. To study the effects of p19A on mitochondria, I will use both our in vivo novel mouse model of colitis and an ex vivo intestinal organoid model where mice or human patient IECs are cultured into a mini-gut structure. I will also explore the efficacy of mitochondria-targeted drugs to counteract the effects of p19A in both models. The proposed study will lead to better understandings of IBD pathogenesis and may help the development of novel IBD drugs.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chan, Jocelyn J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~